Galmed Pharma (GLMD) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- S&P 500, Dow futures muted ahead of jobs data; chips, software stocks rise
- Oil prices drop as investors weigh potential Hormuz deal between Iran, Gulf states
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Why a solid NFP report could spark a stock selloff, according to JPMorgan
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Nielsen to acquire DoubleVerify in merger deal
- Apollo to acquire easyJet for £5.7B in cash deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 4, 2022 8:01 AM EDTTEL AVIV, Israel, Aug. 4, 2022 /PRNewswire/ --Â Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis and other fibrotic indications, provides today a business update and reports financial results for the three and six months ended June 30, 2022.
Recent Developments
Discontinuing the Open Label Part of the ARMOR study having reached its objectives while refocusing research and... More